首页 > 市场调查报告书 > 医疗设备

医学影像诊断

市场调查报告书

商品编码

1594892

光学临床前成像的全球市场

Optical Preclinical Imaging

出版日期: 2024年11月22日 | 出版商:

Global Industry Analysts, Inc. | 英文 93 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2030年，全球光学临床前影像市场预计将达到9.369亿美元

2023年全球光学临床前影像市场估计为6.274亿美元，预计2030年将达到9.369亿美元，在2023-2030年分析期间复合年增长率为5.9%。生物发光/萤光成像系统是本报告分析的细分市场之一，预计复合年增长率为 7.0%，到分析期结束时将达到 5.369 亿美元。在分析期间，独立萤光成像系统领域的复合年增长率预计为 5.0%。

美国市场预计1.64亿美元，中国预期复合年增长率9.2%

预计 2023 年美国光学临床前影像市场规模将达到 1.64 亿美元。中国作为世界第二大经济体，预计到 2030 年市场规模将达到 2.207 亿美元，2023-2030 年分析期间复合年增长率为 9.2%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 3.5% 和 4.7%。在欧洲，德国的复合年增长率预计为 4.3%。

全球光学临床前影像市场—主要趋势与驱动因素总结

光学临床前影像如何改变生物医学研究？

光学临床前成像已成为生物医学研究中的革命性工具，使科学家能够以前所未有的细节可视化活体动物模型中的细胞和分子过程。传统上，研究人员依靠侵入性方法来监测疾病进展和治疗效果，但光学成像技术的进步正在提供非侵入性的即时见解，可以帮助临床前研究带来一场革命。萤光和生物发光成像等技术使研究人员能够监测细胞和亚细胞层面的生物变化，有助于更深入地了解复杂的生物机制。这种能力在癌症研究中特别有价值，光学成像使研究人员能够追踪肿瘤的生长、转移和治疗反应，而无需多次侵入性操作。透过允许研究人员对同一主题进行长期研究，光学成像最大限度地减少了实验所需的动物数量，并符合生物医学研究中的伦理考量。

除了加强癌症研究之外，光学临床前影像还具有先进的免疫学、神经科学和感染疾病研究。即时可视化免疫细胞行为和病原体-宿主相互作用的能力提供了可以导致新治疗方法发现的重要资料。例如，萤光成像可以追踪免疫细胞对感染疾病和肿瘤的反应，从而深入了解如何调节免疫反应以改善治疗结果。同样，光学成像技术可用于神经科学研究，以监测神经活动和大脑功能。透过可视化疾病模型中的神经元通讯和退化，研究人员可以更好地了解阿兹海默症和帕金森氏症等神经退化性疾病，并为标靶治疗铺平道路。因此，光学临床前影像处于现代生物医学研究的前沿，并已成为增进我们对各种病理状况理解的重要工具。

此外，将光学成像与 MRI 和 CT 等其他成像技术相结合的多模态成像系统的发展进一步提高了临床前研究的能力。这些系统提供补充资料，提高生物学见解的精确度和深度。例如，光学成像提供了更高的灵敏度来检测特定的生物标记物，而 CT 和 MRI 添加了结构讯息，将这些观察置于受试者的解剖框架内。透过以这种方式整合功能和解剖资料，研究人员可以更全面地资料疾病进展和治疗意义。多模态成像将光学临床前成像带入了新领域，巩固了其作为转化研究中重要技术的作用，旨在弥合临床前知识和临床应用之间的差距。

为什么光学成像在药物开发上受到青睐？

光学临床前成像使製药公司能够敏感地评估候选药物在体内的功效、分布和安全性，并已成为药物开发的首选技术。这种非侵入性技术为药物发现和临床前测试提供了一种更快、更具成本效益的方法，显着缩短了新治疗方法从实验室到临床试验所需的时间。在萤光/生物发光成像中，药物和生物标记物被标记有特定的萤光或发光探针，当它们与目标细胞或蛋白质相互作用时会发光。这些讯号提供有关药物如何与特定生物标的相互作用的即时信息，从而更容易评估治疗效果并识别潜在的副作用。光学成像使研究人员能够快速筛检多种候选药物，简化有前途的化合物的选择，并在进入昂贵的临床阶段之前完善剂量和给药方法。

光学成像在药物动力学和动态研究中也很有用，可以追踪药物如何在体内移动以及它们产生什么作用。利用萤光标记，科学家可以可视化药物在体内的吸收、分布、代谢和排泄（ADME）过程。这些资料对于确定最佳给药方案和了解药物化学性质如何影响生物有效性和功效至关重要。光学成像的即时回馈对于理解抗体和基因疗法等生技药品的行为特别有价值，这些生物製剂通常需要精确的标靶和监测。此外，光学成像使研究人员能够测量药物在体内特定部位的生物分布，从而使研究人员能够确定药物是否对其预期目标产生影响，而不会在非目标器官中积累，从而导致毒性。能达到目标。这种细节程度是其他成像技术难以达到的，凸显了光学成像在药物开发中的独特优势。

光学临床前成像由于其在癌症、感染疾病和代谢性疾病等多种疾病模型中的灵活性，已成为转化研究的重要工具。光学成像使製药公司能够使用基因工程生物体在各种疾病模型中对候选药物进行严格的测试，这些生物体表达与所研究的疾病相关的特定标记。例如，研究代谢紊乱的研究人员可以利用光学成像即时观察葡萄糖摄取和脂质代谢的变化，为新药的治疗效果提供有价值的见解。光学成像对这些疾病模型和研究目标的适应性使研究人员能够做出资料主导的决策，从而加速发现有效和安全的治疗方法，这使得光学成像在开发平臺中发挥重要作用。

光学临床前影像如何推进精准医学？

精准医学领域旨在根据个别患者特征量身定制治疗，极大地受益于光学临床前影像的进步。透过提供高度详细的分子和细胞见解，光学成像使研究人员能够在个人化层面上了解疾病的潜在机制，这对于开发标靶治疗至关重要。这种能力在肿瘤学中特别有价值，肿瘤异质性意味着不同的患者对治疗的反应不同。光学成像使研究人员能够分析活体模型中肿瘤的分子特征，并识别出显示哪些患者会对特定治疗产生反应的生物标记。这种精准主导的方法可以客製化治疗计划，最大限度地提高治疗效果，同时最大限度地减少不必要的副作用，这是精准医学的核心目标。

光学成像在了解影响疾病感受性和治疗效果的遗传因素方面也发挥着重要作用。例如，在基因编辑研究中，萤光标记可用于即时追踪基因修饰的效果，显示特定的基因修饰如何影响疾病进展或药物疗效。这将使研究人员能够探索基因治疗的潜力并评估基于 CRISPR 的治疗的安全性和有效性。此外，光学成像可以可视化特定基因突变如何影响细胞路径，使科学家能够确定罕见和复杂疾病的潜在治疗标靶。这种洞察力对于推进精准医学至关重要，精准医学旨在根据患者独特的遗传特征和疾病特征量身定制治疗方案。

在免疫治疗领域，光学临床前影像为开发利用人体免疫系统对抗肿瘤的个人化癌症治疗开闢了新的可能性。生物发光成像等光学成像技术使研究人员能够观察免疫细胞和肿瘤之间的相互作用，从而提供有关免疫疗法在体内如何发挥作用的宝贵资料。透过追踪免疫细胞的运动和活动，研究人员可以确定哪些类型的免疫细胞最有效地针对特定的肿瘤类型，以及肿瘤如何逃避免疫反应。这些资讯对于设计更有效的免疫疗法至关重要，这些疗法适合每位患者的免疫特征并符合精准医疗的目标。透过其揭示复杂生物机制的能力，光学临床前成像不仅促进了个性化治疗的发展，而且有助于理解遗传学、免疫和疾病之间复杂的相互作用。

是什么推动了光学临床前影像市场的成长？

光学临床前成像市场的成长受到多种因素的推动，包括成像技术的进步、药物发现投资的增加以及精准医疗的兴起。临床前研究对更准确、非侵入性和经济高效的成像技术的需求正在刺激光学成像系统的创新，特别是在萤光、生物发光和多模态成像方面。这些技术使研究人员能够对疾病机制、药物疗效和生物标记表达进行高度详细的研究，提供推动学术研究和药物开发的关键资料。光学成像的可及性和灵敏度以及提供即时回馈的能力使其成为临床前研究的宝贵工具，随着药物开发变得更加复杂和资料驱动，临床前研究不断扩大。药物发现和疾病研究对先进成像解决方案的需求是推动光学临床前成像市场向前发展的关键因素。

另一个重要的驱动因素是对精准医学的日益重视，光学临床前影像对于根据患者个体情况开发标靶治疗至关重要。由于精准医学寻求在分子层面上了解疾病，因此光学成像提供了询问疾病模型中的细胞和遗传过程所需的工具，使研究人员能够识别生物标记物，并允许您相应地调整治疗方法。可视化和量化活体模型中生物标记活动的能力与精准医学的目标一致，使得光学成像对于将临床前见解与个人化治疗联繫起来至关重要。研究和临床实践中向精准医学的持续转变正在刺激光学成像技术的发展。研究人员需要能够促进个人层面资料收集和分析的工具，最终帮助创建更有效和个人化的治疗方案。

此外，临床前研究中对微创技术的日益关注正在推动光学成像的采用，以实现纵向研究，减少动物使用并提高资料一致性。光学成像的非侵入性对于对同一物件进行重复测量特别有价值，可以减少对大样本大小的需求并满足动物研究的道德标准。製药公司和学术机构越来越多地转向光学成像来优化临床前测试。随着对伦理研究实践的持续支持以及对高效药物开发平臺的需求，对光学临床前成像解决方案的需求将稳步增长，支持生物医学研究的进步并推动光学成像市场的成长。

部分

模式（生物发光/萤光成像系统、独立萤光成像系统、光学+X射线/光学+CT）、最终用户（製药/生物技术公司、研究机构、其他最终用户）

受访企业范例（共42例）

BioTek Instruments, Inc.
Bruker Corporation
Fujifilm Holdings America Corporation
Fujifilm Holdings Corporation
Magnetic Insight, Inc.
MBF Bioscience
Mediso Ltd.
MILabs BV
Miltenyi Biotec
MR Solutions
PerkinElmer, Inc.
TriFoil Imaging
UVP
Vieworks Co., Ltd.

The global market for Optical Preclinical Imaging estimated at US$627.4 Million in the year 2023, is expected to reach US$936.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Bioluminescence / Fluorescence Imaging Systems, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$536.9 Million by the end of the analysis period. Growth in the Standalone Fluorescence Imaging Systems segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$164.0 Million While China is Forecast to Grow at 9.2% CAGR

The Optical Preclinical Imaging market in the U.S. is estimated at US$164.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$220.7 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Optical Preclinical Imaging Market - Key Trends & Drivers Summarized

How Has Optical Preclinical Imaging Transformed Biomedical Research?

Optical preclinical imaging has emerged as a transformative tool in biomedical research, enabling scientists to visualize cellular and molecular processes in live animal models with unprecedented detail. Traditionally, researchers relied on invasive methods to observe disease progression and treatment efficacy, but advancements in optical imaging technology have revolutionized preclinical studies by offering non-invasive, real-time insights. Techniques such as fluorescence and bioluminescence imaging allow researchers to monitor biological changes at cellular and subcellular levels, facilitating a deeper understanding of complex biological mechanisms. This capability is especially valuable in cancer research, where optical imaging can track tumor growth, metastasis, and responses to therapies without the need for multiple invasive procedures. By allowing researchers to conduct longitudinal studies on the same subject, optical imaging minimizes the number of animals required for experiments, which aligns with ethical considerations in biomedical research.

In addition to enhancing cancer research, optical preclinical imaging has advanced studies in immunology, neuroscience, and infectious diseases. The ability to visualize immune cell behavior and pathogen-host interactions in real-time provides critical data that can drive new therapeutic discoveries. For example, fluorescence imaging can track immune cells as they respond to infections or tumors, providing insights into how immune responses could be modulated to improve treatment outcomes. Similarly, optical imaging techniques are instrumental in neuroscience research, where they are used to monitor neural activity and brain function. By visualizing how neurons communicate or degenerate in disease models, researchers can better understand neurodegenerative diseases like Alzheimer’s and Parkinson’s, paving the way for targeted therapies. Thus, optical preclinical imaging has established itself as an indispensable tool for advancing our understanding of a wide array of medical conditions, positioning it at the forefront of modern biomedical research.

Moreover, the development of multimodal imaging systems, which combine optical imaging with other imaging techniques such as MRI or CT, has further extended the capabilities of preclinical studies. These systems provide complementary data that enhance the accuracy and depth of biological insights. For instance, while optical imaging offers high sensitivity for detecting specific biomarkers, CT and MRI add structural information that contextualizes those findings within the anatomical framework of the subject. This integration of functional and anatomical data enables researchers to build a more comprehensive picture of disease progression and therapeutic impact. With multimodal imaging, optical preclinical imaging is entering new realms of sophistication, solidifying its role as a pivotal technology for translational research aimed at bridging the gap between preclinical findings and clinical applications.

What Makes Optical Imaging a Preferred Technique in Drug Development?

Optical preclinical imaging has become a preferred technique in drug development, allowing pharmaceutical companies to evaluate the efficacy, distribution, and safety of drug candidates in vivo with high sensitivity. This non-invasive technique offers a faster and more cost-effective method for drug discovery and preclinical testing, significantly reducing the time it takes to bring new treatments from the laboratory to clinical trials. In fluorescence and bioluminescence imaging, drugs or biological markers are tagged with specific fluorescent or luminescent probes that emit light when interacting with target cells or proteins. These signals provide real-time information on how drugs interact with specific biological targets, making it easier to assess therapeutic effectiveness and identify potential side effects. With optical imaging, researchers can quickly screen multiple drug candidates, streamline the selection of promising compounds, and refine dosage and delivery methods before moving into costly clinical stages.

Furthermore, optical imaging is instrumental in pharmacokinetics and pharmacodynamics studies, which track how drugs move through and affect the body. By using fluorescent markers, scientists can visualize drug absorption, distribution, metabolism, and excretion (ADME) processes within living organisms. This data is essential for determining optimal dosing regimens and understanding how a drug's chemical properties impact its bioavailability and efficacy. Optical imaging's real-time feedback is especially valuable in understanding the behavior of biologics, such as antibodies and gene therapies, which often require precise targeting and monitoring. In addition, optical imaging can measure drug biodistribution at specific sites within the body, helping researchers determine if a drug effectively reaches its intended target without accumulating in non-targeted organs, which could lead to toxicity. This level of detail is difficult to achieve with other imaging techniques, highlighting the unique advantages of optical imaging in drug development.

The flexibility of optical preclinical imaging to work across various disease models, including cancer, infectious diseases, and metabolic disorders, has made it an essential tool in translational research. Optical imaging enables pharmaceutical companies to conduct rigorous testing of drug candidates in a wide range of pathological models, often using genetically modified organisms that express specific markers relevant to the disease being studied. For instance, researchers studying metabolic disorders can use optical imaging to observe changes in glucose uptake or lipid metabolism in real-time, providing valuable insights into the therapeutic effects of new drugs. This adaptability of optical imaging across disease models and research goals underscores its vital role in the drug development pipeline, empowering researchers to make data-driven decisions that accelerate the discovery of effective and safe treatments.

How Is Optical Preclinical Imaging Advancing Precision Medicine?

The field of precision medicine, which aims to customize treatments based on individual patient characteristics, has greatly benefited from advancements in optical preclinical imaging. By providing highly detailed molecular and cellular insights, optical imaging enables researchers to understand the underlying mechanisms of diseases at a personalized level, which is essential for developing targeted therapies. This capability is particularly valuable in oncology, where the heterogeneity of tumors means that different patients respond to treatments differently. With optical imaging, researchers can analyze the molecular profile of tumors in live models, identifying biomarkers that indicate which patients may respond to specific therapies. This precision-driven approach allows for the customization of treatment plans, maximizing therapeutic outcomes while minimizing unnecessary side effects, which is the core objective of precision medicine.

Optical imaging also plays a critical role in understanding genetic factors that influence disease susceptibility and treatment responses. In gene-editing studies, for example, fluorescent markers can be used to track the effects of gene modifications in real-time, showing how certain genetic alterations impact disease progression or drug efficacy. This allows researchers to explore potential gene therapies and assess the safety and effectiveness of CRISPR-based treatments. Additionally, optical imaging can visualize how specific genetic mutations affect cellular pathways, enabling scientists to identify potential therapeutic targets for rare and complex diseases. This level of insight is essential for advancing precision medicine, where the goal is to tailor treatments based on a patient’s unique genetic profile and disease characteristics.

In the realm of immunotherapy, optical preclinical imaging has opened up new possibilities for developing personalized cancer treatments that harness the body’s immune system to fight tumors. Optical imaging techniques, such as bioluminescence imaging, allow researchers to observe immune cell interactions with tumors, providing valuable data on how immunotherapies perform within a living organism. By tracking the movement and activity of immune cells, researchers can identify which types of immune cells are most effective in targeting specific tumor types and monitor how tumors evade immune responses. This information is crucial for designing more effective immunotherapies tailored to individual patients' immune profiles, aligning with the goals of precision medicine. Through its ability to reveal intricate biological mechanisms, optical preclinical imaging is not only advancing the development of personalized treatments but also helping to unravel the complex interactions between genetics, immunity, and disease.

What Is Fueling the Growth in the Optical Preclinical Imaging Market?

The growth in the optical preclinical imaging market is driven by several factors, including advancements in imaging technology, increased investment in drug discovery, and the rise of precision medicine. The demand for more accurate, non-invasive, and cost-effective imaging techniques in preclinical studies has fueled innovation in optical imaging systems, particularly in fluorescence, bioluminescence, and multimodal imaging. These technologies allow researchers to conduct highly detailed studies on disease mechanisms, drug efficacy, and biomarker expression, providing critical data that drive both academic research and pharmaceutical development. The accessibility and sensitivity of optical imaging, combined with its ability to deliver real-time feedback, make it a valuable tool for preclinical studies, which continue to expand as drug development becomes more complex and data-driven. This need for sophisticated imaging solutions in drug discovery and disease research is a key factor propelling the optical preclinical imaging market forward.

Another significant driver is the increasing emphasis on precision medicine, where optical preclinical imaging is essential for developing targeted therapies based on individual patient profiles. As precision medicine seeks to understand diseases at a molecular level, optical imaging provides the tools necessary to study cellular and genetic processes within disease models, enabling researchers to identify biomarkers and tailor therapies accordingly. The ability to visualize and quantify biomarker activity in live models aligns with the goals of precision medicine, making optical imaging indispensable for translating preclinical findings into personalized treatments. The ongoing shift toward precision medicine in both research and clinical practice has spurred growth in optical imaging technologies, as researchers require tools that can facilitate data collection and analysis on an individual level, ultimately helping to create more effective and personalized treatment options.

Furthermore, the growing focus on minimally invasive techniques in preclinical research is driving the adoption of optical imaging, as it allows for longitudinal studies with reduced animal usage and improved data consistency. Optical imaging’s non-invasive nature is particularly valuable for conducting repeated measures on the same subject, reducing the need for large sample sizes and aligning with ethical standards in animal research. Pharmaceutical companies and academic institutions are increasingly adopting these methods to optimize their preclinical studies, as optical imaging reduces costs and enhances experimental efficiency. With continued support for ethical research practices and the need for efficient drug development pipelines, the demand for optical preclinical imaging solutions is expected to rise steadily, supporting advancements in biomedical research and driving the growth of the optical imaging market.

SCOPE OF STUDY:

The report analyzes the Optical Preclinical Imaging market in terms of US$ Thousand by the following End-Use; Modality, and Geographic Regions/Countries:

Segments:

Modality (Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems, Optical + X-Ray / Optical + CT); End-Use (Pharma & Biotech Companies, Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

BioTek Instruments, Inc.
Bruker Corporation
Fujifilm Holdings America Corporation
Fujifilm Holdings Corporation
Magnetic Insight, Inc.
MBF Bioscience
Mediso Ltd.
MILabs B.V.
Miltenyi Biotec
MR Solutions
PerkinElmer, Inc.
TriFoil Imaging
UVP
Vieworks Co., Ltd.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Global Economic Update
- Optical Preclinical Imaging - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Advancements in Molecular Imaging Techniques Drive Adoption of Optical Preclinical Imaging
- Increased R&D Expenditure in Biotechnology Propels Demand for Preclinical Imaging
- Rising Demand for Cancer Research Boosts the Need for Optical Imaging
- Technological Advancements in Fluorescence Imaging Sets the Stage for Market Growth
- Government Funding for Biomedical Research Strengthens the Optical Imaging Market
- Expanding Drug Discovery Programs Drive Growth in Optical Preclinical Imaging
- Innovations in Imaging Agents Propel Demand for Optical Imaging
- Advancements in 3D Imaging Drive Demand for Optical Preclinical Solutions
- Increasing Use of Imaging in Stem Cell Research Strengthens Market Growth
- Use of Optical Imaging for Neurodegenerative Disease Research Expands Opportunities
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 2: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 3: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 5: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 6: World 16-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 8: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 9: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 10: World Optical Preclinical Imaging Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Optical Preclinical Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 15: World Historic Review for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 16: World 16-Year Perspective for Bioluminescence / Fluorescence Imaging Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Standalone Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 18: World Historic Review for Standalone Fluorescence Imaging Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 19: World 16-Year Perspective for Standalone Fluorescence Imaging Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Optical + X-Ray / Optical + CT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 21: World Historic Review for Optical + X-Ray / Optical + CT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 22: World 16-Year Perspective for Optical + X-Ray / Optical + CT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 23: USA Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 24: USA Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 25: USA 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 26: USA Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 27: USA Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 28: USA 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
CANADA
- TABLE 29: Canada Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 31: Canada 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 32: Canada Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 33: Canada Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 34: Canada 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
JAPAN
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 35: Japan Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 36: Japan Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 37: Japan 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 38: Japan Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 39: Japan Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 40: Japan 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
CHINA
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 41: China Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 42: China Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 43: China 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 44: China Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 45: China Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 46: China 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
EUROPE
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 47: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 48: Europe Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 49: Europe 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 50: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Optical Preclinical Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 52: Europe 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 53: Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 55: Europe 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
FRANCE
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 56: France Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 57: France Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 58: France 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 59: France Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 60: France Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 61: France 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
GERMANY
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 62: Germany Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 63: Germany Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 64: Germany 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 65: Germany Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 66: Germany Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 67: Germany 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
ITALY
- TABLE 68: Italy Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 69: Italy Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 70: Italy 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 71: Italy Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 72: Italy Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 73: Italy 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 74: UK Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 75: UK Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 76: UK 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 77: UK Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 78: UK Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 79: UK 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
SPAIN
- TABLE 80: Spain Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 81: Spain Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 82: Spain 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 83: Spain Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 84: Spain Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 85: Spain 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
RUSSIA
- TABLE 86: Russia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 87: Russia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 88: Russia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 89: Russia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 90: Russia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 91: Russia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 93: Rest of Europe Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 94: Rest of Europe 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 96: Rest of Europe Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 97: Rest of Europe 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 99: Asia-Pacific Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 100: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 102: Asia-Pacific Historic Review for Optical Preclinical Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 103: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 106: Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
AUSTRALIA
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
- TABLE 107: Australia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 108: Australia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 109: Australia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 110: Australia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 111: Australia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 112: Australia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
INDIA
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
- TABLE 113: India Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 114: India Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 115: India 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 116: India Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 117: India Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 118: India 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
SOUTH KOREA
- TABLE 119: South Korea Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 120: South Korea Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 121: South Korea 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 122: South Korea Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 123: South Korea Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 124: South Korea 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
- TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 126: Rest of Asia-Pacific Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 129: Rest of Asia-Pacific Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
LATIN AMERICA
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
- TABLE 131: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 132: Latin America Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 133: Latin America 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 134: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 135: Latin America Historic Review for Optical Preclinical Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 136: Latin America 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
- TABLE 137: Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 138: Latin America Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 139: Latin America 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
ARGENTINA
- TABLE 140: Argentina Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 141: Argentina Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 142: Argentina 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 143: Argentina Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 144: Argentina Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 145: Argentina 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
BRAZIL
- TABLE 146: Brazil Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 147: Brazil Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 148: Brazil 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 149: Brazil Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 150: Brazil Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 151: Brazil 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
MEXICO
- TABLE 152: Mexico Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 153: Mexico Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 154: Mexico 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 155: Mexico Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 156: Mexico Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 157: Mexico 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
- TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 159: Rest of Latin America Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 160: Rest of Latin America 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 162: Rest of Latin America Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 163: Rest of Latin America 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
MIDDLE EAST
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
- TABLE 164: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 165: Middle East Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 166: Middle East 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 167: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 168: Middle East Historic Review for Optical Preclinical Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 169: Middle East 16-Year Perspective for Optical Preclinical Imaging by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
- TABLE 170: Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 171: Middle East Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 172: Middle East 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
IRAN
- TABLE 173: Iran Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 174: Iran Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 175: Iran 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 176: Iran Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 177: Iran Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 178: Iran 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
ISRAEL
- TABLE 179: Israel Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 180: Israel Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 181: Israel 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 182: Israel Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 183: Israel Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 184: Israel 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
SAUDI ARABIA
- TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 186: Saudi Arabia Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 187: Saudi Arabia 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 189: Saudi Arabia Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 190: Saudi Arabia 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
- TABLE 191: UAE Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 192: UAE Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 193: UAE 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 194: UAE Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 195: UAE Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 196: UAE 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
- TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 198: Rest of Middle East Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 199: Rest of Middle East 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 201: Rest of Middle East Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 202: Rest of Middle East 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030
AFRICA
- Optical Preclinical Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
- TABLE 203: Africa Recent Past, Current & Future Analysis for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 204: Africa Historic Review for Optical Preclinical Imaging by End-Use - Pharma & Biotech Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 205: Africa 16-Year Perspective for Optical Preclinical Imaging by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
- TABLE 206: Africa Recent Past, Current & Future Analysis for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 207: Africa Historic Review for Optical Preclinical Imaging by Modality - Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 208: Africa 16-Year Perspective for Optical Preclinical Imaging by Modality - Percentage Breakdown of Value Sales for Bioluminescence / Fluorescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray / Optical + CT for the Years 2014, 2024 & 2030